(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $6.41
Utstedt: 14 feb 2024 @ 20:41
Avkastning: -25.97%
Forrige signal: feb 14 - 19:57
Forrige signal:
Avkastning: 2.72 %
Live Chart Being Loaded With Signals
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology...
Stats | |
---|---|
Dagens volum | 3.88M |
Gjennomsnittsvolum | 2.47M |
Markedsverdi | 705.24M |
EPS | $0 ( 2024-03-11 ) |
Neste inntjeningsdato | ( $-0.180 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.65 |
ATR14 | $0.0100 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-26 | Summer Road Llc | Buy | 930 851 | Common Stock, $0.0001 par value per share |
2024-02-22 | Dugel Pravin | Buy | 1 282 469 | Stock Option (Right to Buy) |
2024-02-22 | Dugel Pravin | Buy | 854 979 | Common Stock |
2024-02-22 | Nayak Sanjay | Buy | 244 550 | Stock Option (Right to Buy) |
2024-02-22 | Nayak Sanjay | Buy | 80 300 | Common Stock |
INSIDER POWER |
---|
97.80 |
Last 98 transactions |
Buy: 9 847 283 | Sell: 256 052 |
Volum Korrelasjon
Ocular Therapeutix Inc Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Ocular Therapeutix Inc Korrelasjon - Valuta/Råvare
Ocular Therapeutix Inc Økonomi
Annual | 2023 |
Omsetning: | $58.44M |
Bruttogevinst: | $53.16M (90.96 %) |
EPS: | $-1.010 |
FY | 2023 |
Omsetning: | $58.44M |
Bruttogevinst: | $53.16M (90.96 %) |
EPS: | $-1.010 |
FY | 2022 |
Omsetning: | $51.49M |
Bruttogevinst: | $46.95M (91.18 %) |
EPS: | $-0.830 |
FY | 2021 |
Omsetning: | $43.52M |
Bruttogevinst: | $39.12M (89.88 %) |
EPS: | $-0.0900 |
Financial Reports:
No articles found.
Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.